Dr Gregory Quinlan is a Senior Research Fellow based in the Critical Care, Pulmonary Vascular and Sleep Science Section at the Royal Brompton Campus of the National Heart and Lung Institute (NHLI). He heads the Oxygen Chemistry Group within Critical Care Medicine which is composed of postdoctoral scientists, PhD students and research technicians. He also has an honorary contract with the Royal Brompton Hospital which reflects the translational nature of much of his research.
Dr Quinlan graduated from Thames Polytechnic in 1982 and then worked as a Senior Scientific Officer at the National Institute of Biological Standards and Control for eight years with Professor John MC Gutteridge. During this time research interests were devoted to the investigation of role of oxidative stress and transition metal ions in potential mechanisms of antibiotic action as well as studies on mechanisms of lipid peroxidation. Several of the publications produced during this time have become seminal works. In 1991 Dr Quinlan along with Professor Gutteridge joined the NHLI in order to help establish the then fledgling Critical Care Research group under the leadership of Professor Tim Evans.
Dr Quinlan undertook PhD studies on a part-time basis and was awarded his PhD from the University of London in 1995. Since then Dr Quinlan has remained with the group and is now the principal scientific researcher within the department.
Dr Quinlan has gained an international reputation for innovative research into the pathogenesis of critical illness which together with previous research interests has resulted in over 100 scientific articles. His research efforts as part of Professor Evans group have uniquely contributed to current understanding of the mechanisms involved in the onset and progression of acute lung injury and its severest manifestation the acute respiratory distress syndrome, with particular emphasis on the role of oxidative and nitroasive stress and aberrant iron metabolism. The role haemolysis and the pro-inflammatory action of free haem and haemoglobin in scenarios relevant to acute lung injury and sepsis are areas of particular research interest.
Dr Quinlan is currently supervising five PhD students and has previously supervised seven clinical and non-clinical studentships and fellowships to a successful conclusion.
Along with Dr Mark Griffiths, Dr Quinlan heads a core facility for the Biomedical Research Unit (BRU) at the Royal Brompton Hospital, and is deputy head and scientific lead of the Acute Respiratory Failure Consortium within the BRU.
Dr Quinlan is also a reviewer for the International journal Critical Care Medicine and provides regular manuscript reviews for at least 10 other respiratory and scientific journals, he also provides grant reviews for research councils, medical research charities and foreign governments.
Finally, Dr Quinlan has obtained research funding, from the British Heart Foundation, Wellcome Trust, Dunhill Medical Trust, Henry Smith Charity, JP Moulton Charitable Foundation, the Garfield Weston Trust and the Plasma Protein Therapeutics Association.
et al., 2019, Plasma S100A8/A9 heterodimer is an early prognostic marker of acute kidney injury associated with cardiac surgery, Biomarkers in Medicine, Vol:13, ISSN:1752-0363, Pages:205-218
et al., 2018, Development of a novel UHPLC-MS/MS-based platform to quantify amines, amino acids and methylarginines for applications in human disease phenotyping, Scientific Reports, Vol:8, ISSN:2045-2322
et al., 2018, The Hepcidin/Ferroportin axis modulates proliferation of pulmonary artery smooth muscle cells, Scientific Reports, Vol:8, ISSN:2045-2322
et al., 2018, Pulmonary Arterial Hypertension: Iron Matters, Frontiers in Physiology, Vol:9, ISSN:1664-042X
et al., 2018, Stabilised ferroportin activity affects pulmonary vascular cells responses: implications for pulmonary hypertension, 28th International Congress of the European-Respiratory-Society (ERS), European Respiratory Society, ISSN:0903-1936